Curaleaf Holdings (CURLF) Net Cash Flow (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Net Cash Flow of $15.5 million for Q4 2024, up 165.12% year-on-year from $5.9 million in Q1 2024, and up 537.11% on a QoQ basis from $2.4 million in Q3 2024.
Curaleaf Holdings (CURLF) Net Cash Flow (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Net Cash Flow for 6 consecutive years, with $15.5 million the latest figure, recorded in Q4 2024.
- Quarterly Net Cash Flow rose 165.12% year-over-year to $15.5 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $15.5 million (up 165.56% YoY) and the FY2025 annual result came in at -$6.1 million, down 139.05% from the prior year.
- Net Cash Flow advanced to $15.5 million in Q4 2024 per CURLF's latest filing, from $2.4 million in the prior quarter.
- Over the last five years, Net Cash Flow for CURLF reached as high as $47.4 billion in Q2 2023 and fell as low as -$47.5 billion in Q1 2023.
- A 5-year average of $7.4 million and a median of -$2.1 million in 2020 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 90231.44% in 2023 against a maximum downside of 84894.18% in 2023.
- Year by year, Net Cash Flow stood at -$4.1 million in 2020, then tumbled by 355.73% to -$18.7 million in 2021, then jumped by 280.6% to $33.8 million in 2022, then plunged by 170.59% to -$23.9 million in 2023, then jumped by 165.12% to $15.5 million in 2024.
- According to Business Quant data, Net Cash Flow over the past three periods registered $15.5 million, $2.4 million, and -$41.9 billion for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 15.54 Mn |
| Dec 31, 2024 | 15.54 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | -41.93 Bn |
| Jun 30, 2024 | -41.93 Bn |
| Mar 31, 2024 | 41.93 Bn |
| Mar 31, 2024 | 41.93 Bn |
| Dec 31, 2023 | -23.86 Mn |
| Dec 31, 2023 | -23.86 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Jun 30, 2023 | 47.40 Bn |
| Jun 30, 2023 | 47.40 Bn |
| Mar 31, 2023 | -47.48 Bn |
| Mar 31, 2023 | -47.48 Bn |
| Dec 31, 2022 | 33.80 Mn |
| Dec 31, 2022 | 33.80 Mn |
| Sep 30, 2022 | -26.01 Mn |
| Sep 30, 2022 | -26.01 Mn |